It is often seen that successful investors are prone to the habit of picking up such stock which may be a bit under the radar and rather unexplored by most investors. They pick those stocks up before they rally and hence, end up making significant profits.
While it is impossible to predict how a stock may perform, it may be a good idea to take a look at some of those stocks. This brings us to the subject of Positron Corporation (OTCMKTS:POSC), which is a highly innovative company and may be worth tracking at this point in time by investors.
Trading Data
On Tuesday, POSC stock ended flat at $0.9494 with more than 1.4K shares, compared to a volume of 4.6K shares. The stock moved within a range of $0.7126 – 0.9494 after opening trade at $0.8253.
About The Company
This article is going to provide you with a closer look into the nature of Positron Corporation’s business and also give you a glimpse into the recent developments which may have an effect on the stock price. The company is involved in the highly innovative nuclear medicine PET imagine device space.
The devices manufactured by Positron Corporation specialize in cardiac Positron Emission Tomography imaging and which is regarded as the finest methodology in terms of cardiac diagnostics. In addition to its highly innovative PET technology, the company also provides practice solutions and clinical services.
These services help healthcare providers in their efforts to diagnose coronary artery problems far more accurately and improve outcomes considerably. The company is also working on an advanced PET/CT imagine device that is going to provide nuclear cardiologists with the option of using the full scope of nuclear imaging.
Positron Corporation Announces First Step in Validation of its New PET-CT Device
Yesterday, the company came into the news cycle after it announced that it had been successful in buying its first PET/CT system and the system was now going to be delivered by Positron Corporation’s partner Neusoft Medical Systems. The system has been named ‘Affinity PET-CT’ by the company and the product was now being sent from China to the company’s validation partner, which is based out of the United States.
The product is expected to arrive in the United States by the end of September this year. It was noted yesterday that it marked a major new milestone for the company in its quest to launch the Affinity PET-CT nuclear imaging device. It should be noted that it would not be long before Positron Corporation announces the name of the physician, hospital, and other major participants who are going to be a part of the entire validation process with regard to the device. Performance results are also going to be revealed by Positron Corporation following the completion of the validation process.
However, that is not all. Positron Corporation is working on several fronts with regard to this particular product and it seems the company is determined to get the product to the market as soon as it possibly can. Positron Corporation also announced yesterday that it was ready to submit the 510K systems application to the United States Food and Drug Administration at some point in the coming weeks. It is now going to be interesting to see if the latest developments lead to any major move in the Positron Corporation stock or not.
Technical Data
POSC stock is trading above the 20-Day and 50-Day Moving averages of $0.84 and $0.79 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.88. The company has a total market capitalization of $13.29 million. The stock is up 35% over the past month.
